Continuous Glucose Monitor Biosensor Patent Landscape
Continuous Glucose Monitor Biosensor Patent Landscape in 2026
The continuous glucose monitor biosensor space is highly concentrated, with Dexcom commanding the largest single share of the top-ranked filers and the United States dominating as the lead filing office. The field has expanded on a multi-year basis, though annual volume has eased from its 2022 peak, signalling a maturing competitive structure where incremental system-integration and digital-health filings now outnumber core sensor chemistry work.
Dexcom leads a concentrated field with a clear tier gap over challengers
Dexcom holds the top-ranked position among all applicants, followed by Abbott Diabetes Care and Cambridge Enterprise. The top five filers together account for half of the combined volume of the hundred largest filers, indicating meaningful concentration at the front of the pack.
A pronounced tier gap separates Dexcom from the rest of the field. Abbott Diabetes Care and Cambridge Enterprise occupy a clear second tier, while the remaining ranked applicants each hold substantially smaller positions, creating an asymmetric competitive structure.
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 1 | Dexcom Inc | 65 | |
| 2 | Abbott Diabetes Care Inc | 30 | |
| 3 | Cambridge Enterprise Ltd | 20 | |
| 4 | Bigfoot Biomedical Inc | 15 | |
| 5 | Tandem Diabetes Care Inc | 11 | |
| 6 | F HOFFMANN LA ROCHE & CO AG | 11 | |
| 7 | I-SENS Inc | 10 | |
| 8 | Insulet Corporation | 9 | |
| 9 | Allez Health Inc | 8 | |
| 10 | Roche Diabetes Care Inc | 7 |
| # | Applicant | Patent records | Share |
|---|---|---|---|
| 11 | Animas Corporation | 7 | |
| 12 | Jiangsu Yuekai Biotechnology Co Ltd | 6 | |
| 13 | Zhejiang Poctech Co Ltd | 6 | |
| 14 | Jiangsu Yuwell POCT Biological Technology Co Ltd | 6 | |
| 15 | Optum Labs LLC | 5 | |
| 16 | BioLinq Inc | 5 | |
| 17 | Budiman Erwin S | 3 | |
| 18 | Roche Diagnostics GmbH | 3 | |
| 19 | Hayter Gary A | 3 | |
| 20 | Children’s Medical Center Corporation | 3 |
Dexcom’s dominant position, reinforced by a positive recent-period trajectory, suggests it has built a defensible portfolio covering both core diagnostic and adjacent digital-health claims. Challengers aiming to compete must navigate this dense incumbent coverage or seek differentiation in under-represented branches.
Patent applications filed within roughly the last 18 to 24 months are subject to publication lag and will be under-counted in this corpus; recent-period figures should be read as a floor rather than a ceiling. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filing activity plateaued after a 2022 peak; diagnostic claims dominate the technology mix
The trend chart and technology-composition breakdown together reveal a field that is still active on a multi-year view but has shifted from rapid growth toward consolidation, with software and connectivity branches now materially supplementing the core diagnostic base.
Annual filing trend
Annual filings climbed to a peak in 2022 before easing. The 2024 and 2025 bars should be read as preliminary figures subject to publication lag; the apparent softening is consistent with a maturing field rather than a confirmed decline.
↗ Hover for values · click a bar to ask EurekaTechnology composition
A61B (Diagnosis & surgery) dominates the branch mix by a wide margin, followed by G16H (Healthcare informatics) and A61M (Devices for body fluids). The presence of G06F, H04W, and G09G branches reflects a broadening toward data-processing, wireless connectivity, and display-interface innovation alongside traditional sensor hardware.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Interoperability and data exchange capabilities be…
The current subject matter is directed to an ecosystem that enables interconnection of a blood glucose monitor and a continuous glucose monitor for data exchange and processing of shared data. The communication of data and instructions enables user-facing functionality and feedback to a user. The connection between the blood glucose monitor and the… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Systems and methods for leveraging smartphone feat… | 247 |
| 2 | Methods for reducing false hypoglycemia alarm occu… | 214 |
| 3 | Overnight closed-loop insulin delivery with model … | 144 |
| 4 | Systems and methods for leveraging smartphone feat… | 137 |
| 5 | Overnight closed-loop insulin delivery with model … | 135 |
| 6 | Overnight closed-loop insulin delivery with model … | 107 |
| 7 | Systems and methods for leveraging smartphone feat… | 90 |
| 8 | Systems and methods for leveraging smartphone feat… | 86 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents. Some patent titles may be shown in their original, non-English language where an accurate translation could not be guaranteed.
What the competitive structure means for R&D investment decisions
The combination of a maturing lifecycle, high concentration at the top, and active co-filing alliances shapes where meaningful white space remains and which entry strategies carry the most realistic prospects.
Field is at plateau: annual filings eased from the 2022 peak
The lifecycle stage is classified as Maturity, with annual filings having plateaued near their 2022 peak. The multi-year window still shows positive growth of 17%, but the post-peak easing signals that foundational sensor IP is largely staked out. New entrants should expect to compete on system-level differentiation, algorithm accuracy, or connectivity rather than basic electrochemical sensing claims.
Lifecycle: MaturityTop five filers hold half of the largest-filer volume
The top five applicants — Dexcom, Abbott Diabetes Care, Cambridge Enterprise, Bigfoot Biomedical, and Tandem Diabetes Care — together account for 50% of the combined patent-record volume of the hundred largest filers. This concentration creates freedom-to-operate challenges for new market entrants and raises the cost of challenging incumbents through litigation or design-around efforts.
High concentrationAbbott–Cambridge alliance is the dominant co-filing relationship
The most active co-applicant pairing is Abbott Diabetes Care and Cambridge Enterprise, sharing 18 co-filed records, likely reflecting joint closed-loop insulin-delivery research. F. Hoffmann-La Roche and Roche Diagnostics represent the second most active pair with 4 co-filed records, reflecting intra-group portfolio coordination. These alliances signal that academic-industry partnerships remain a viable route for building foundational CGM algorithm and system-level IP.
Co-filing alliancesUS-centric filing with selective international prosecution
The United States is the lead filing office by a substantial margin, with Europe (EPO) and WIPO (PCT) as the next most common venues, followed by Canada and China. The relatively limited prosecution in Japan and South Korea suggests that some filers may be under-protecting commercially important Asian markets, creating both risk for portfolio holders and potential freedom-to-operate in those jurisdictions for others.
US-dominantGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Abbott Diabetes Care Inc | Cambridge Enterprise Ltd | 18 |
| F. Hoffmann-La Roche & Co AG | Roche Diagnostics GmbH | 4 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
Dexcom leads on diagnostics and digital health; Abbott and Cambridge anchor a close second tier through co-filed system IP
The two player profiles below capture the dominant incumbent and the most active challenger alliance, drawing on recent filing momentum and technology focus to differentiate strategic posture.
Dexcom Inc
Dexcom holds 65 patent records in the corpus, the largest position of any single filer. Its technology focus spans A61B 5 (core diagnostic sensing), G16H 40 (healthcare informatics), and G06F 3 (digital data processing), reflecting a strategy that covers both hardware sensing and the software stack above it. Recent filing momentum is positive at +13% versus the prior period, indicating continued active portfolio expansion rather than harvest-mode inactivity.
65 patent recordsAbbott Diabetes Care Inc
Abbott Diabetes Care holds 30 patent records and pursues a technology mix led by G16H 20 (healthcare informatics / treatment management), A61B 5, and A61M 5 (devices for body fluids), indicating a stronger emphasis on closed-loop delivery systems relative to Dexcom. Abbott’s momentum is classified as a new entrant signal in the most recent filing window, suggesting a renewed or accelerated push into this specific technology cluster. Its 18-record co-filing alliance with Cambridge Enterprise reinforces the algorithmic and system-integration angle of its portfolio.
30 patent records| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| Dexcom Inc | 18 | ▲ +13% |
| Abbott Diabetes Care Inc | 1 | ▲ new entrant |
| Bigfoot Biomedical Inc | 3 | ▲ new entrant |
| Tandem Diabetes Care Inc | 8 | ▲ new entrant |
| Allez Health Inc | 6 | ▲ new entrant |
| Insulet Corporation | 7 | ▲ new entrant |
Digital processing, display control, and wireless connectivity are under-served relative to the diagnostic core
While A61B dominates the technology mix, several adjacent IPC branches have materially lower filing density and represent areas where the dominant players have not yet built the same depth of coverage, leaving potential room for focused entrants or academic-industry partnerships.
G06F · Electric Digital Data Processing
With 41 patent records and an 8% share of IPC branch volume, G06F is the largest of the under-served adjacent branches. Coverage of sensor-data algorithms, edge-computing integration, and user-interface logic for CGM devices is relatively sparse compared to the diagnostic core. A team with software or embedded-systems expertise could build a defensible position here without directly conflicting with the densest incumbent claims, particularly in real-time data interpolation and predictive analytics at the device level.
Search this in Eureka →H04W · Wireless Communication Networks
H04W holds 18 patent records at a 3% share, indicating limited dedicated filing on CGM-specific wireless transmission protocols, low-power Bluetooth integration, and secure data relay to mobile platforms. As CGM devices increasingly function as nodes in broader connected-health ecosystems, wireless communication IP becomes strategically important. Entrants with telecommunications or IoT backgrounds could address latency, interference, and security angles that existing CGM-focused filers have not yet prioritized.
Search this in Eureka →How leading applicants differ in their IPC branch emphasis
Strength of each leader across the main technology routes.
| Player | A61B 5 · Diagnosis & surgery | G16H 20 · Healthcare informatics | G16H 40 · Healthcare informatics | A61M 5 · Devices for body fluids | G06F 3 · Electric digital data processing |
|---|---|---|---|---|---|
| Dexcom Inc | Strong · 58 | Emerging · 10 | Strong · 33 | Absent | Moderate · 22 |
| Abbott Diabetes Care Inc | Strong · 24 | Strong · 26 | Moderate · 10 | Moderate · 11 | Absent |
| Cambridge Enterprise Ltd | Strong · 12 | Strong · 17 | Moderate · 4 | Strong · 10 | Absent |
| Tandem Diabetes Care Inc | Strong · 11 | Strong · 6 | Moderate · 3 | Strong · 11 | Absent |
| Animas Corporation | Strong · 8 | Strong · 7 | Strong · 7 | Strong · 7 | Absent |
| Bigfoot Biomedical Inc | Strong · 16 | Absent | Absent | Emerging · 2 | Absent |
| F. Hoffmann-La Roche & Co AG | Strong · 11 | Absent | Absent | Emerging · 2 | Absent |
Frequently asked questions
The corpus contains 159 patent families in scope, providing the baseline for all landscape statistics in this report.
Dexcom Inc is the top-ranked filer with 65 patent records, roughly double the count of the second-ranked applicant, Abbott Diabetes Care Inc, which holds 30 patent records.
On a multi-year basis the corpus shows a 17% recent growth figure, but annual filings have eased from a 2022 peak, placing the field in a Maturity lifecycle stage. The most recent 18 to 24 months are subject to publication lag and will be under-counted.
The United States is the lead filing office, followed by Europe (EPO), WIPO (PCT), Canada, and China. Japan and South Korea have relatively limited prosecution depth, which may represent under-protected territory for some portfolio holders.
The most active co-applicant pairing is Abbott Diabetes Care and Cambridge Enterprise with 18 co-filed records, most likely linked to closed-loop insulin delivery and CGM algorithm research. F. Hoffmann-La Roche and Roche Diagnostics share 4 co-filed records reflecting intra-group coordination.
The adjacent branches with the lowest relative filing density include G06F (electric digital data processing) at 8% IPC branch share, H04W (wireless communication networks) and G16Z (specific-application computing) each at 3%, and G08B (signalling and alarm systems) at 2%. These areas are sparsely covered relative to the dominant A61B diagnostic class and may offer entry points for filers with software, connectivity, or embedded-systems expertise.
Ready to map your own CGM biosensor landscape?
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.